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ABSTRACT
Objective In 1991, the Medical Research Council
(MRC) Vitamin Study demonstrated that folic acid taken
before pregnancy and in early pregnancy reduced the
risk of a neural tube defect (NTD). We aimed to estimate
the number of NTD pregnancies that would have been
prevented if ﬂour had been fortiﬁed with folic acid in the
UK from 1998 as it had been in the USA.
Design Estimates of NTD prevalence, the preventive
effect of folic acid and the proportion of women taking
folic acid supplements before pregnancy were used to
predict the number of NTD pregnancies that would have
been prevented if folic acid fortiﬁcation had been
implemented.
Setting Eight congenital anomaly registers in England
and Wales.
Main outcome measures The prevalence of
pregnancies with an NTD in the UK and the number of
these pregnancies that would have been prevented if
folic acid fortiﬁcation had been implemented.
Results From 1991 to 2012, the prevalence of NTD
pregnancies was 1.28 (95% CI 1.24 to 1.31) per 1000
total births (19% live births, 81% terminations and
0.5% stillbirths and fetal deaths ≥20 weeks’ gestation).
If the USA levels of folic acid fortiﬁcation from 1998
onwards had been adopted in the UK, an estimated
2014 fewer NTD pregnancies would have occurred.
Conclusions Failure to implement folic acid
fortiﬁcation in the UK has caused, and continues to
cause, avoidable terminations of pregnancy, stillbirths,
neonatal deaths and permanent serious disability in
surviving children.
INTRODUCTION
In 1991, the Lancet published the report of the
Medical Research Council (MRC) Vitamin Study
randomised controlled trial, which showed that
taking folic acid before conception reduced the risk
of a neural tube defect (NTD) pregnancy by an
estimated 72%.1 It is not possible to achieve a high
enough daily intake of folate to provide such a
reduction in risk from dietary modiﬁcation alone;
so, taking folic acid supplements or eating food for-
tiﬁed with folic acid is necessary. Mandatory fortiﬁ-
cation of ﬂour with folic acid has been introduced
in 78 countries, including the USA, Canada and
Australia, but despite evidence that such fortiﬁca-
tion is effective,2–9 mandatory folic acid fortiﬁca-
tion of ﬂour has not been introduced in the UK. In
1992, the UK Department of Health advised
women to take folic acid supplements (in the form
of tablets or capsules) before pregnancy to reduce
their risk of an NTD pregnancy.10
The aim of this study was to determine the
prevalence of pregnancies and live births with an
NTD in the UK and to estimate the potential effect
there would have been on the prevalence of NTDs
if fortiﬁcation of ﬂour with folic acid had been
implemented in 1998 as was done in the USA.
METHODS
Data on the number of diagnoses and terminations
with an NTD are available from the British Isles
Network of Congenital Anomaly Registers
(BINOCAR). Although the registers do not cover
the whole of the UK, these ﬁgures are considered
to be more complete than those from the Ofﬁce
for National Statistics (ONS)11 and are submitted
as part of the European Surveillance of Congenital
Anomalies (EUROCAT), which spans a greater
period than the data collation and publication
initiated by BINOCAR in 2009.12 EUROCAT is a
European network of population-based registries
for the epidemiologic surveillance of congenital
anomalies (http://www.eurocat-network.eu/) and
surveys over 1.7 million births from 25 countries in
Europe.13 Data from BINOCAR registers about live
births, late fetal deaths (>20 weeks’ gestation) and
terminations of pregnancy due to fetal anomaly at
any gestation (TOPFA) with an NTD were obtained
from the EUROCATwebsite for 1991–2012, as this
website allows bespoke prevalence tables to be
obtained interactively.14 Data were available for all
of Wales, but were only available in regions of
What is already known on this topic
▸ Folic acid has a substantial effect in preventing
neural tube defects, but most women do not
take folic acid supplements.
▸ Population-wide fortiﬁcation of ﬂour with folic
acid is an effective preventive measure.
What this study adds
▸ An estimated 2000 pregnancies associated with
a neural tube defect would have been
prevented if the UK had adopted the same
fortiﬁcation regimen adopted in the USA from
1998.
▸ Fortiﬁcation of ﬂour with folic acid should be a
priority UK public health policy.
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England in which a congenital anomaly register (CAR) was
active, and were not available for Scotland or Northern Ireland.
From 1991 to 2012, eight regional CARs provided data to
EUROCAT (see table 1). Details on the data and their collection
are available at http://www.eurocat-network.eu/. Registers use
multiple sources of information to ascertain cases, including
maternity, neonatal and paediatric records; fetal medicine, cyto-
genetic, pathology and medical genetics records; specialist ser-
vices including paediatric cardiology; and hospital discharge and
child health records.
Anomalies were coded according to the EUROCAT guide
1.3.15 NTDs include anencephalus, encephalocele and spina
biﬁda. Cases were coded as having encephalocele only if there
was no mention of anencephalus. Similarly, cases were coded as
having spina biﬁda only if there was no mention of anencepha-
lus or encephalocele.
The annual change in prevalence of NTD pregnancies was esti-
mated within each register over the time period during which the
register was active. These annual changes were then combined to
provide an overall estimate using a random effects multilevel
Poisson regression model nested within registers. The total
number of births covered by each regional CAR was the exposure
variable, and these were available from the EUROCAT website.
This model estimated the prevalence of NTDs in each two yearly
period adjusted for the speciﬁc CARs. Similarly, a random effects
multilevel logistic regression model nested within registers was
used to model the proportion of pregnancies that ended in a
termination. All analyses were performed in Stata V.12.16
The number of NTD diagnoses and births occurring in the
whole of the UK in a year was estimated by multiplying the
prevalence in the regions with registries by the total number of
births in the UK in that year.
In the USA, mandatory fortiﬁcation with 140 mg of folic acid
per 100 g of enriched cereal grain product was fully implemen-
ted in 1998, and has been estimated to provide 200 mg of folic
acid per day to women of childbearing age.17 Wald et al18 esti-
mated that for the average serum folate concentration for young
women in Britain (5 ng/mL), an increase in folic acid intake of
200 mg per day would increase the average serum folate concen-
tration by 1.88 ng/L and hence reduce the risk of NTDs by
about 23%. A recent paper assessing the extent of folic acid sup-
plementation among almost half a million women in England
has estimated that the proportion of women taking folic acid
supplements declined from 39.6% in 1999 to 27.8% in 2012.19
This is in agreement with an additional study from the West
Midlands in England, which reported on 111 000 pregnant
women of whom 25.5% took folic acid before pregnancy from
2009 to 2012.20 In order to calculate a conservative estimate of
the potential reduction in NTDs due to fortiﬁcation, it was
assumed that fortiﬁcation would only have beneﬁtted those
women not taking supplements and that the reduction in risk
would have been 23%.18 For a conservative estimate, the higher
proportions of women taking supplements from Bestwick
et al19 (from 39.6% to 27.8%) were used rather than the
25.5% estimated from the West Midlands.20 For example, in
2012, 27.8% of women took a folic acid supplement and there-
fore, the effect of fortiﬁcation would be (1–0.278)×0.23 that is,
a 17% reduction in pregnancies with an NTD.
RESULTS
Table 1 shows the prevalence of NTD pregnancies per 1000
births by register. From 1991 to 2012, the prevalence of NTD
pregnancies was 1.28 (95% CI 1.24 to 1.31) per 1000 total
births and of NTD live births was 0.20 (0.16 to 0.25) per 1000
live births. The proportion of affected pregnancies terminated
was 81%, and 0.5% were late stillbirths or fetal deaths
≥20 weeks’ gestation.
Figure 1 shows the prevalence of NTD pregnancies (live
births, late fetal losses after 20 weeks’ gestation and termina-
tions with an NTD) from 1991 to 2012 in two yearly periods.
Online supplementary appendix table 1 gives the annual preva-
lence of NTD pregnancies from 1991 to 2012. There was no
statistically signiﬁcant decrease in the prevalence in the 14 years
from 1998 (the start of fortiﬁcation in the USA) to 2012 (−7%;
95% CI −17% to +3%).
Figure 1 shows the prevalence of spina biﬁda (excluding anen-
cephaly), anencephaly (with or without spina biﬁda) and ence-
phalocele individually. Again, there was no statistically
signiﬁcant change in the prevalence of spina biﬁda (−8%; 95%
CI −21% to +8%), anencephaly (0%; −15% to +18%) and
encephalocele (−20%; −43% to + 14%) from 1998 to 2012.
Table 2 shows that if fortiﬁcation had been implemented at
the level adopted by the USA from 1998 to 2012, there would
have been an estimated 2014 fewer pregnancies affected with an
NTD in the UK (1798 in England and Wales, 152 in Scotland
and 64 in Northern Ireland). An estimated 21% reduction in
the prevalence of NTDs would have occurred, threefold greater
than that observed.
DISCUSSION
Our results show that in the UK between 1998 and 2012, there
was little, if any, change in the prevalence of pregnancies with
Table 1 Prevalence of pregnancies with an NTD and proportion of NTD pregnancies resulting in a termination of pregnancy by register
Register
Years of notification
to EUROCAT
Number of pregnancies
with an NTD
Prevalence of pregnancies with
an NTD per 1000 births (95% CI)
Proportion of pregnancies (%) with
an NTD resulting in a termination of
pregnancy (95% CI)
South West England 2005–2012 446 1.1 (1.0 to 1.2) 82 (79 to 86)
Thames Valley 1991–2012 398 1.2 (1.1 to 1.4) 82 (79 to 86)
North West Thames 1991–2004 826 1.2 (1.2 to 1.3) 83 (80 to 86)
East Midlands and South Yorkshire 1998–2012 1156 1.2 (1.1 to 1.2) 77 (74 to 79)
Merseyside and Cheshire 1995–1999 183 1.3 (1.1 to 1.5) 82 (76 to 87)
Wessex 1994–2012 668 1.3 (1.2 to 1.4) 86 (84 to 89)
Northern England 2000–2012 603 1.4 (1.3 to 1.6) 79 (76 to 83)
Wales 1998–2012 772 1.5 (1.4 to 1.6) 82 (80 to 85)
Total 1.3 (1.2 to 1.3) 81 (80 to 82)
EUROCAT, European Surveillance of Congenital Anomalies; NTD, neural tube defect.
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an NTD, while in the USA, quickly following the introduction
of mandatory fortiﬁcation of ﬂour with folic acid in 1998, there
was an approximate 23% reduction in the occurrence of
affected births.2–4 Given the evidence from the MRC Vitamin
Study1 regarding the efﬁcacy of folic acid in preventing NTDs,
the failure of Britain to fortify ﬂour with folic acid has had sig-
niﬁcant consequences.
The recent evidence that only 28% of pregnant women in
England in 2012 took folic acid supplements at the correct time
indicates that, in practice, recommending folic acid supplemen-
tation is largely ineffective.19 In addition, a recent report
showed that the median level of serum folate in women from
the UK aged 16–49 was 7.1 ng/mL in samples obtained from
2008 to 2012.21 This is in comparison with the median levels
of 5 ng/mL observed in the samples collected from 1983 to
1991 from pregnant women in the MRC Vitamin Study;1 an
increase of only 2.1 ng/mL over 20 years with an estimated 22%
of women still having a serum folate <5 ng/mL.21 The absence
of any material change in NTD rates in the past 14 years is,
therefore, not surprising. Our study demonstrates that an esti-
mated threefold greater reduction in the prevalence of NTDs
would have been achieved if fortiﬁcation of ﬂour with folic acid
had been adopted. In Chile, the level of ﬂour fortiﬁcation
adopted is higher than that in the USA (2.2 μg/100 g ﬂour vs
1.4 μg/100 g).22 If this level of fortiﬁcation had been adopted,
about double (3500) the number of pregnancies with an
affected baby would have resulted in an unaffected baby, and
there would have been an estimated 36% reduction in the
prevalence of NTDs. Given the known beneﬁts, there is no
reason not to adopt the level of fortiﬁcation introduced in Chile
in all countries throughout the world.
Folic acid intake either in the form of supplements or in forti-
ﬁed ﬂour is remarkably safe. It is a water-soluble vitamin that
can be readily excreted, and while there has been speculation
over possible hazards, notably cancer, none have been demon-
strated. In particular, a large meta-analysis of randomised trials
involving the use of folic acid supplements failed to provide any
suggestion of a cancer risk.23 Therefore, health authorities
should not specify a maximum daily intake, as this minimises
the fortiﬁcation level due to concerns of a small proportion of
the population exceeding this maximum daily intake. In Chile,
such concerns led to the unwarranted reduction of fortiﬁcation
level in 2012 (2.2 to 1.8 μg folic acid/100 g wheat ﬂour).24 It
has been demonstrated that the higher the dose of folic acid the
higher the degree of protection from NTDs, and therefore,
health authorities should seek to adopt the highest fortiﬁcation
level judged to be acceptable.18
Mandatory food fortiﬁcation with folic acid has been shown
to be an extremely cost-effective way to provide this nutrient
Figure 1 Prevalence of all neural
tube defects (NTDs), spina biﬁda,
anencephaly and encephalocele
diagnoses (live births, late fetal losses
after 20 weeks’ gestation and
terminations) per 1000 live births;
eight regional congenital anomaly
registers in the UK: 1991–2012.
Table 2 Estimation of the number of pregnancies with a neural
tube defect (NTD) that would have been prevented if folic acid
fortification of flour had been implemented in 1998 in the UK
Year of
notification
Number of
pregnancies
with an
NTD*
Proportion
of women
taking
folic acid
before
pregnancy
(%)†
Estimated
additional
percentage
reduction in
women if
folic acid
fortification
implemented
from 1998 (%)
Number of
pregnancies
with an NTD
that would
have been
prevented
by folic acid
fortification
A B C=(1−B/100)×23 AxC
1998 936 39.6 0‡ 0
1999 898 39.6 14 125
2000 898 39.6 14 125
2001 884 39.6 14 123
2002 915 35.6 15 136
2003 931 35.6 15 138
2004 910 35.6 15 135
2005 905 31.8 16 142
2006 931 31.8 16 146
2007 875 31.8 16 137
2008 863 29.9 16 139
2009 1019 29.9 16 164
2010 1022 29.9 16 165
2011 1034 27.8 17 172
2012 1012 27.8 17 168
Total
(1998–2012)
2014
*From online supplementary appendix table 1.
†From ref. 19.
‡Conservative assumption of no reduction in the first year of fortification.
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during the periconceptional period and reduce the number of
children affected by NTDs.8 24 25
An advantage of our study is that it was based on 36% of all
births in England and Wales. There is no reason to believe that
the prevalence of NTD pregnancies in regions in England not
covered by CARs will differ from the regions covered by CARs,
particularly with such a large sample (36%). We used data from
CARs rather than data from the ONS, which have been shown
to be incomplete and which ceased congenital anomaly data col-
lection in 2011. The data from the CARs are all coded consist-
ently, and have been shown to have high ascertainment rates
due to obtaining notiﬁcations from multiple sources.11
Information on whether the women who had had an affected
pregnancy took folic acid supplements before and during the
ﬁrst trimester of pregnancy would have been very informative,
but unfortunately was not available.
The number of pregnancies with an NTD that would have
been prevented by folic acid fortiﬁcation is based on the estimate
that the risk of an NTD pregnancy will be reduced by 23% in
women who are not taking a folic acid supplement. The 23%
was derived from a model based on the synthesis of many studies
of the dose response of women taking folic acid and the risk of
NTD pregnancies according to serum folate at levels close to the
levels of fortiﬁcation being considered. The model accurately
predicted the results from the MRC Vitamin Study when much
higher levels of folic acid were taken in the form of supplements
of 4 μg/day and also accurately predicted the observed reduction
in the USA. The 23% is, therefore, reasonably reliable.
The proportions of women taking folic acid before pregnancy
are based on a study of nearly half a million women and hence
are precise estimates (their 95% CI are on average under 1% in
width). If an estimated risk reduction 10% lower than the ori-
ginal 23% (ie, 21% instead of 23%) and the upper 95% CI for
the proportions taking folic acid are used, the estimated total
number of pregnancies with an NTD that could have been pre-
vented will still be over 1800 compared with the 2000 origin-
ally estimated, indicating the robustness of the estimates.
The failure to implement folic acid fortiﬁcation has resulted
in the conception of an estimated 2000 pregnancies affected
with an NTD in the UK from 1998 to 2012. This failure will
continue to result in an estimated additional 150 affected preg-
nancies each year. Of these, about half will be due to spina
biﬁda without anencephaly (see ﬁgure 1), and, in the absence of
termination of pregnancy, nearly all of these would result in the
birth of individuals with serious disability. Therefore, the failure
to fortify resulted in an estimated 1000 people with serious dis-
ability and this is continuing with about 75 more individuals
with disability being born every year. In comparison, the thal-
idomide epidemic, in total caused about 500 people to be dis-
abled in the UK.26 Justiﬁably, steps were introduced to
immediately halt the epidemic, and regulatory precautions were
introduced to avoid another similar epidemic. Unfortunately, no
such sense of urgency has been applied to the prevention of
spina biﬁda. It is illogical to take preventive public health action
to avoid a drug-induced congenital anomaly, but to largely
ignore action in relation to a congenital anomaly which can be
prevented by vitamin fortiﬁcation of ﬂour, when the failure to
act has resulted in, and continues to result in, many more
serious cases. It is a public health failure that Britain has not
implemented the fortiﬁcation of ﬂour with folic acid for the
prevention of spina biﬁda and other NTDs.
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